Baolan H. Li
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.
Journal: Cancer communications (London, England)
Published: January 08, 2026
Dose-dependent efficacy of CX1003 in NSCLC immunotherapy: High dose for T cell response, low dose for apoptosis.
Journal: International immunopharmacology
Published: June 15, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: April 24, 2025
A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).
Journal: Future oncology (London, England)
Published: December 04, 2024
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: September 14, 2024
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: August 25, 2024
Immuno-combined treatment versus radio-combined treatment in limited-stage small-cell lung cancer.
Journal: Therapeutic advances in medical oncology
Published: June 20, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).
Journal: Cancer communications (London, England)
Published: March 08, 2024
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.
Journal: Cancer cell
Published: January 03, 2024
Survival Analysis of 159 Patients With Advanced Non-Small-Cell Lung Cancer Resistant to First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
Journal: Clinical Medicine Insights. Oncology
Published: February 25, 2023
Last Updated: 09/26/2026